1. Introduction
Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells (over 10% by definition) in the bone marrow (BM) [ 1 ], the presence of monoclonal immunoglobulin (Ig) in the serum or urine, osteolytic bone lesions, renal disease, and immunodeficiency. It is mainly a disease of old patients, with a median age at diagnosis of 65–70 years. In almost all cases, MM is preceded by a premalignant disease well known as monoclonal gammopathy of undetermined significance (MGUS) [ 2 , 3 ], that affects 2% of the population above the age of 50. Both genetic and environmental factors have been implicated in MGUS progression to MM [ 4 ], but the reasons why it happens in only a small proportion of patients are yet unclear. Progression to MM is correlated with changes in the BM microenvironment, including increased angiogenesis, suppression of the immune response, and increased bone resorption [ 5 ]. More than 80% of MM patients develop osteolytic bone disease, often associated with hypercalcemia and skeletal-related events such as severe bone pain, vertebral compression fractures, and pathologic fractures. Importantly, pathologic fractures affect 40% to 50% of MM patients, increasing the risk of death by more than 20% compared with patients without fractures [ 6 , 7 ]. Thus, osteolytic lesions have a negative impact on both quality of life and survival of patients.
It was well documented that the interaction of malignant plasma cells with BM stromal cells (BMSCs) is crucial for the homing and growth of malignant plasma cells as well as for the impairment of osteoclast (OC), the bone resorbing cell, and osteoblast (OB), the bone forming cell, activities. In particular, in areas adjacent to myeloma cells, OC activity increases, resulting in enhanced bone resorption, and OB activity declines with consequent reduced bone formation [ 8 ]. Therefore, bone remodeling, in which OC and OB activities are tightly coupled, is disrupted in MM.
It was also demonstrated that several factors produced as a result of MM cell—BMSC interactions also alter the functions of the host immune cells, thus interfering with immune surveillance, preventing immune mediated tumor rejection [ 9 ], and contributing to the MM worsening.
Here, we discuss the pathogenesis of MM bone disease and focus on advances in our understanding of its biology, with particular regard on the role of bone and immune cells in producing cytokines critical for the induction of osteolysis development in MM.
2. The Biology of MM Bone Disease
The cross-talk between cells located in the BM microenvironment and bone cells is tightly regulated. Many components of the bone microenvironment are responsible for the proliferation of tumor cells [ 10 – 12 ], that, in turn, promote the formation of a permissive microenvironment for their survival [ 13 – 15 ]. The BM microenvironment refers to both cells located in the BM (malignant plasma cells, stromal and immune cells) and noncellular components, the extracellular matrix (ECM), composed of proteins such as collagen, laminin, and fibronectin and the extracellular fluid containing cytokines and growth factors. The signaling cascades induced by the cells located in the BM microenvironment as well as by bone cells affect not only the propagation and survival of tumor cells but also the differentiation and activation of OCs and OBs, thus contributing to the development of osteolytic lesions.
3. MM Cells
The BM of patients with MM contains malignant plasma cells that directly, by the production of cytokines, or indirectly, by stimulating BM cell secretion of other factors, contribute to the unbalance between bone resorption and formation, resulting in the development of osteolytic lesions [ 16 ]. In fact, bone destruction develops adjacent to MM cells and not in areas of normal BM. In particular, MM cells directly produce factors implicated in both OC activation and OB inhibition. Among the factors implicated in OC activation, it was demonstrated that malignant plasma cells produce decoy receptor 3 (DcR3), interleukin-3 (IL-3), macrophage inflammatory protein-1 α (MIP-1 α ), macrophage inflammatory protein-1 β (MIP-1 β ), and tumor necrosis factor- α (TNF- α ) ( Figure 1 ).
We demonstrated that DcR3, a member of the TNF receptor superfamily and known to be involved in OC differentiation [ 17 ], was overexpressed by malignant plasma cells and T-lymphocytes obtained from MM patients with osteolysis [ 18 , 19 ].
Lee et al. demonstrated the ability of MM cells to overexpress another pro-osteoclastogenic factor: IL-3 [ 20 ]. Furthermore, they found that BM plasma samples from MM patients stimulated OC formation in vitro , and the effect was reversed by the addition of a neutralizing antibody to IL-3 [ 20 ]. Other authors reported that IL-3 promotes both the increase of pre-OC number and their fusion into mature OCs [ 21 ], thus confirming the potential role of IL-3 as an OC stimulatory factor in MM bone disease. In addition, a contribution of IL-3 in the inhibition of bone formation in MM has also been reported. It inhibits OB differentiation of primary mouse and human stromal cells treated with BMP-2 in a dose-dependent way without affecting cell growth [ 22 ]. Thus, IL-3 appears to be a potential mediator of myeloma bone disease, playing a dual role in MM both stimulating OC activity and inhibiting OB differentiation. All these data are in agreement with the IL-3 elevated levels found in BM and blood of patients with MM [ 23 ].
Another cytokine produced at high levels by MM cells is MIP-1 α [ 24 ]. Its high BM serum levels correlate with osteolytic lesions and survival in MM patients [ 24 ]. It is a low molecular weight chemokine which can interact with its receptors, CCR1 and CCR5, expressed by monocytes and BMSCs [ 25 – 27 ]. MIP-1 α acts as a chemoattractant [ 28 ] and has a role in hematopoiesis, OC recruitment, and differentiation in BM [ 25 , 29 , 30 ]. It was demonstrated that in MM bone disease MIP-1 α induces OC differentiation from monocytes as well as from immature dendritic cells (DC) by transdifferentiation [ 31 ]. This reciprocal effect of MIP-1 α on DC and OC differentiation further contributes to the immunosuppression and bone destruction in MM. MIP-1 α also induces survival, growth, and chemotaxis of MM cells [ 32 ]. The dual activity of MIP-1 α has been targeted in vivo with different strategies. In a mouse model of MM bone disease, it was shown that both antisense sequence and neutralizing antibody against MIP-1 α restored bone remodelling and inhibited tumor growth [ 33 , 34 ]. Moreover, the inhibition of CCR1 was associated with impairment of osteoclastogenesis and OC-induced tumor cell proliferation in vitro , suggesting that the MIP-1 α /CCR1 pathway is an important target in MM bone disease [ 35 ].
MIP-1 β is a highly homologous chemokine of MIP-1 α constitutively secreted by MM cells, that similarly to MIP-1 α induces the development of osteolytic bone lesions [ 36 ].
About the possibility that MM cells produce also receptor activator of NF- κ B ligand (RANKL), a well known pro-osteoclastogenic molecule; literature data are still controversial. RANKL binds its receptor, RANK, expressed by OC precursors, and induces OC formation in the presence of Macrophage colony-stimulating factor (M-CSF) [ 37 ]. Alternatively, RANKL could interact with osteoprotegerin (OPG), a secreted member of the TNF receptor superfamily, that, by binding to and blocking the effect of RANKL [ 38 ], inhibits OC formation. Thus, the ratio of OPG/RANKL is crucial for OC development, and its unbalance is associated with bone disease [ 39 ]. Several studies conducted on human MM cells from patients [ 40 – 42 ], human MM cell lines, and a murine MM cell line [ 43 ] reported RANKL expression by myeloma cells. On the contrary, other studies were not able to detect RANKL expression in human myeloma cell lines or primary myeloma cells [ 44 – 48 ]. Independently on the possibility that MM cells could produce RANKL, it was well documented that its overexpression in BM microenvironment correlated with BMSCs and T-lymphocytes production, as will be discussed. These data were in agreement with the high BM plasma levels of RANKL found in MM patients [ 45 ] and with the high circulating RANKL serum levels demonstrated by Jakob et al. [ 49 ]. In particular, these last researchers found that serum total-RANKL reflects advanced disease, lytic bone destruction, and poor prognosis in MM [ 49 ].
Malignant plasma cells not only produce cytokines involved in OC survival and formation but also secrete molecules responsible for the inhibition of OB activity. It was demonstrated that MM cells secrete soluble frizzled-related proteins-2 and -3 (sFRP-2 and -3) [ 50 – 52 ], Dickkopf-1 (DKK-1) [ 53 ], and sclerostin [ 54 ] ( Figure 1 ), all implicated in the inhibition of the canonical wingless-type (Wnt) signaling. The canonical Wnt pathway is one of the most relevant signaling regulating OB differentiation. Wnts are secreted cysteine-rich glycoproteins known as regulators of hematopoietic and mesenchymal cell differentiation as well as of embryonic development [ 55 – 57 ]. The activation of canonical Wnt signaling, induced by binding of Wnt proteins to both Frizzled receptor and low-density lipoprotein receptor-related protein (LRP-5/6) coreceptor, is followed by β -catenin translocation into the nucleus, [ 58 , 59 ] resulting in the activation of major OB transcription factors. Thus, the presence, in the bone microenvironment, of secreted antagonists, such as sFRPs which interfere with Wnt/Frizzled receptor binding, or DKK proteins and sclerostin, which bind the coreceptor LRP5/6 [ 60 ], could negatively regulate osteoblastogenesis. In particular, sFRP-2 and -3 have been reported to be produced both by primary MM cells from patients and MM cell lines. It was shown that recombinant sFRP-2 inhibits OB differentiation [ 50 ] and that neutralizing sFRP-2 in conditioned media from MM cell lines partially reversed the inhibition of OB differentiation. In addition, it was also demonstrated that sFRP-3 was upregulated in MM patients [ 51 , 52 ]. Moreover, it was reported that DKK-1, highly expressed in BM of MM patients with osteolytic lesions, is apparently involved in early stages of bone disease [ 53 ]. It was implied in the development of MM osteolytic lesions because of both its inhibitory effect on OB formation and its effect in increasing OC formation through the upregulation of RANKL and inhibition of OPG secretion, by inhibiting Wnt-3A [ 61 ]. Similarly, we demonstrated the expression of sclerostin by myeloma cells and the possibility that its contribution in the development of MM bone disease could be related to both a direct induction of OB suppression with reduced bone formation and an indirect activation of OC bone resorption through the unbalanced RANKL/OPG ratio [ 54 – 62 ]. Moreover, Terpos et al. demonstrated that patients with active myeloma have elevated circulating sclerostin levels, which correlate with advanced disease features including severe bone disease [ 63 ].
MM cells produce TNF- α ( Figure 1 ), a factor that can induce OC formation [ 64 , 65 ], promote MM cell proliferation by increasing Interleukin-6 (IL-6) production by BMSCs [ 66 ], also inhibit mesenchymal stem cell proliferation, and induce mature OB apoptosis [ 64 ]. Moreover, it was recently reported that the OB transcriptor factor Runx2 mediates the effects of TNF- α on OBs [ 67 ]. In particular, they found that the knockdown of Runx2 in mesenchymal stem cells abolished the capacity of TNF- α to block proliferation and differentiation of the cells. These results show an important link between Runx2 and TNF- α 's capacity to inhibit OB differentiation. It was also demonstrated that MM cells selectively suppress BMSCs differentiation into functional OBs, while adipogenesis is not affected [ 68 – 70 ].
4. Bone Marrow Stromal Cells (BMSCs)
MM cells adhere to both BMSCs and ECM into the BM. The adhesion of tumor cells to BMSCs activates many pathways resulting in upregulation of antiapoptotic proteins and cell cycle regulating cytokines [ 71 ]. The main cytokines upregulated are RANKL, IL-6, B-cell activating factor (BAFF), and Activin A ( Figure 1 ).
Specifically, the interaction between MM cells and BMSCs provokes IL-6 secretion in BMSCs via NF- κ B-dependent transcription [ 13 , 72 ]. IL-6 is known to regulate MM cell proliferation and inhibition of both myeloma plasma cell apoptosis [ 73 , 74 ] and OC differentiation [ 75 ].
MM cell adhesion to BMSCs also promotes BAFFproduction via NF- κ B activation [ 76 ]. BAFF is a member of the TNF protein super family, crucial for the maintenance and homeostasis of normal B-cell development, and has been shown to both confer a survival advantage on MM cells [ 76 – 78 ] and to promote RANKL-independent osteoclastogenesis [ 79 ].
Recently, Activin A, a TGF- β family member secreted by BMSCs and OCs after MM cells interaction [ 80 ], was identified to have a crucial role in the pathogenesis of MM bone disease. Activin A modulates bone remodeling by dual activity as OC promoter and inhibitor of OB differentiation. In MM, high Activin A levels in both BM and peripheral blood are associated with advanced bone disease [ 80 ]. Terpos et al. also demonstrated that patients with newly diagnosed symptomatic myeloma had increased circulating Activin A levels compared with controls and that these high levels correlate with advanced features of myeloma [ 81 ].
5. Osteoclasts (OCs)
OCs are bone resorbing cells whose activity and viability are upregulated in MM bone disease because of the presence, in the BM microenvironment, of several factors implicated in their differentiation and activation (RANKL, IL-3, IL-6, MIP-1 α , MIP-1 β , BAFF, DcR3, TNF- α , and Activin A). Not only MM, BMSCs, and immune cells but also OCs represent the source of some pro-osteoclastogenic molecules.
In particular, it was demonstrated that OCs could secrete proteins, such as Activin A [ 80 ] and MIP-1 α [ 82 ], implicated in pre-OC requirement and OC differentiation and activation ( Figure 1 ).
6. Osteoblasts (OBs)
It has been reported that OBs, the bone forming cells, may contribute to MM pathogenesis by both supporting MM cell growth and survival [ 83 ] and contributing to osteolysis development. This could potentially result from the ability of OBs to secrete IL-6 in coculture system with myeloma plasma cells, therefore, inducing MM cell growth ( Figure 1 ). Other mechanisms include the possible role of OBs in stimulating MM cell survival by blocking MM cell apoptosis mediated by TNF-related apoptosis-inducing ligand (TRAIL), through OPG release, a receptor for both TRAIL and RANKL [ 84 ]. Thus, the suppression of OB activity is responsible for both bone destruction and progression of myeloma tumor burden. It was previously described that MM cells secreted several Wnt antagonists that are responsible for suppression of OB differentiation and activity in MM such as DKK-1 [ 53 ], sFRP-2 [ 50 ], sFRP-3 [ 52 ], and sclerostin [ 54 ]. Moreover DKK-1 and sclerostin also disrupt Wnt-regulated OPG and RANKL production by OBs, thus contributing to the bone destruction in MM patients acting not only on OB inhibition but also on OC over-activation. Consistently, all these factors are significantly overexpressed in patients with MM who present lytic bone lesions. Studies have shown that blocking DKK-1 and activating Wnt signaling prevent bone disease in MM but are also associated with a reduction in tumor burden [ 85 – 87 ].
7. Osteocytes
Osteocytes, the bone cells entrapped into the mineralized bone matrix, regulate bone remodelling at least partially, as a result of their cell death triggering OC recruitment. It was recently demonstrated that the number of viable osteocytes was significantly smaller in MM patients with bone lesions than in those without them or in healthy controls and negatively correlated with the number of OCs [ 88 ]. The authors also showed that MM cells cause an upregulation of osteocyte production of the pro-osteoclastogenic cytokine interleukin-11 (IL-11) ( Figure 1 ) and that its expression was higher in the MM patients with bone lesions than in those without them [ 88 ]. Thus among the bone cells, not only OCs and OBs but also osteocytes are involved in MM-induced OC formation.
8. T-Lymphocytes
T cells are immune cells that could regulate OC and OB formation, lifespan, and activity [ 89 , 90 ]. Thus, they could contribute to bone remodeling in both health and disease by producing specific proteins. In the peripheral blood of MM patients, the absolute count of lymphocytes and T cells is often deficient because of a reduction in the number of CD4+ T cells, associated with a significantly decreased ratio of CD4/CD8 T cells, particularly evident in patients with progressive disease [ 91 – 93 ]. Recently, a subclass of CD4+ cells, named regulatory T cells (Tregs), has been identified in MM [ 94 ]. Tregs are cells involved in the control of self-tolerance and immune homeostasis, with suppressive capabilities. These cells are early induced during tumor development and are shown to contribute to tumor tolerance [ 95 , 96 ]. The presence of Tregs in tumors is associated with a poor prognosis [ 97 ]. Patients with many different types of cancers had increased number of Tregs in their blood, tumor mass, and draining lymph nodes [ 98 , 99 ]. Conflicting reports have been published on the frequency of Treg cells in MM patients, with studies showing either their decrease or increase [ 100 – 102 ]. In particular, Prabhala et al. demonstrated that the Tregs were significantly reduced in MGUS and MM subjects [ 103 ]; other authors demonstrated that Treg cells were expanded only in patients with MM at diagnosis, but not in those in remission or in patients with MGUS. Another study involving MM patients and MGUS subjects showed that in both MGUS and untreated MM subjects, as well as treated MM patients, the frequency of Treg cells was increased compared with healthy controls [ 100 ].
In MM, abnormalities within T-cell compartment have also been reported in BM, in which T-cell count increased, and, differently from the peripheral blood, a slightly increased CD4/CD8 ratio was observed. In BM from patients with MM, Dhodapkar et al. demonstrated a high proportion of a distinct lineage of T helper cells producing interleukin 17 (IL-17), called Th17-1 cells [ 104 ]. IL-17 is a cytokine that, in addition to exerting an effect on cell survival [ 105 ], has also been identified as a key mediator of bone disease in MM [ 106 ]. Interestingly, the extent of lytic bone disease appears to be largely mediated by IL-17 produced by Th17-1 cells, independently of the tumor burden, underscoring the crucial interplay of the immune system with the tumor microenvironment in the pathogenesis of MM [ 106 ].
MM-activated T cells have the capacity to secrete a wide variety of pro-osteoclastogenic cytokines that become critical in the induction of osteolysis development in MM. In particular, it was demonstrated that MM T cells produce high levels of IL-3 [ 107 ], RANKL [ 19 ], DcR3 [ 19 ], and TNF- α [ 19 ], all involved in OC formation and activation ( Figure 1 ). We demonstrated that T cells from MM bone disease patients also express high levels of TRAIL, known to be a proapoptotic molecule, and the antiosteoclastogenic protein OPG [ 44 ]. We showed that the OPG/TRAIL interaction could contribute to the elevated formation of long lifespan OCs in MM patients [ 44 ] ( Figure 1 ).
It was also demonstrated the presence of a vicious loop that involved molecules produced by MM cells, T-lymphocytes, and BMSCs [ 108 ]. In particular Giuliani et al. showed that MM cells, by secreting interleukin-7 (IL-7), are able to induce an upregulation of RANKL and a downregulation of interferon- γ (inhibitor of OC formation) secretion by T-lymphocytes [ 109 ]. Other authors demonstrated that IL-7 stimulates IL-6 secretion by BMSCs [ 110 ]. High levels of IL-6 in the BM environment could induce IL-7 production by MM cells, which in turn contribute to maintain high IL-6 levels and stimulate RANKL expression by T cells. In addition, it has been shown that IL-7 can also contribute to the development of osteolytic lesions in MM by inhibiting the differentiation of OBs. In fact, the usage of IL-7 blocking antibodies partially blunts the inhibitory effects of MM cells on OB differentiation [ 111 ].
9. Dendritic Cells (DCs)
DCs are specialized antigen-presenting cells able to initiate immune responses [ 112 ]. DCs derive from myeloid or lymphoid progenitors, and their functions are determined by their origin as well as by their maturation stage, which depends on the signals received from pathogens and T cells. In mice, MM cells or tumor culture-conditioning medium inhibit the differentiation and activation of DCs, as shown by the lower expression of DC-related antigens and compromised capacity to activate allospecific T cells [ 113 ]. It was documented that circulating DCs from MM patients were dysfunctional because they failed to upregulate costimulatory molecules required for activation [ 114 ]. It was suggested that a reduced function of DCs indicates the progression of the disease [ 114 ]. Cytokines actively produced by myeloma cells such as IL-6, IL-10, transforming growth factor- β (TGF- β ), and vascular endothelial growth factor (VEGF) [ 114 ], abundant in the BM as well as in the serum [ 115 ], play a role in preventing the development of functional DCs ( Figure 1 ). Furthermore, DCs from MM patients have reduced phagocytic capacity [ 116 ]. In addition, monocyte-derived DCs exhibit downregulated expression of activation markers and impaired presentation capacity to T cells [ 115 ]. Impaired activity of DCs may be also linked to the upregulation of Tregs [ 117 ], consistently with the observation of some authors that found an increase of Treg number in MM subjects.
10. Novel Antimyeloma-Related Bone Disease Drugs
Current pharmacological strategies in MM have resulted in improved patient overall survival, but no definitive treatment has been as yet achieved. Nowadays, consisting with the improved survival of MM patients, treatment of bone disease has assumed high relevance. Until recently, therapeutic cures for MM bone disease, aimed at reducing the development of new osteolytic lesions, included bisphosphonates, radiotherapy and surgery. Several promising preclinical studies including novel bone-targeted agents suggest that restoring bone homeostasis may lead to inhibition of both bone pain and tumor growth. Here, the current bone-directed drugs are described, with particular regard to their mode of action and targets ( Table 1 ).
Denosumab . Denosumab is a RANKL-neutralizing antibody (AMG165), successfully used in MM patients to inhibit bone resorption markers. A single subcutaneous administration of denosumab induces an important inhibition of bone resorption markers. A randomized clinical trial showed that denosumab inhibits bone resorption and prevents fracture development even in MM patients refractory to bisphosphonates therapy [ 118 ]. Recently, it was also demonstrated that RANKL inhibition with denosumab is as efficacious as zoledronic acid in terms of decreasing fracture development. Denosumab is a well-tolerated drug. Asthenia and peripheral edema represent the only side effects demonstrated on patients that assume the drug [ 119 ]. Currently, denosumab continues to remain in clinical development for MM.
Anti-BAFF—Neutralizing Antibody . BAFF is an MM growth factor produced by OC and BMSC that mediates both MM cells-BMSC adhesion and MM cell survival [ 76 , 120 ]. It was demonstrated that in vivo neutralizing antibodies against BAFF (LY2127399) significantly reduce OC differentiation and inhibit tumor burden [ 121 ]. Currently a clinical trial combining BAFF-neutralizing antibody with bortezomib, a proteasome and NF- κ B signaling pathway inhibitor, is ongoing.
CCR1-Inhibitors . The MIP-1 α /CCR1 pathway is involved in OC differentiation and promotes MM cell survival, making it a possible therapeutic target. In vitro and in vivo studies showed that inhibition of MIP-1 α by antisense strategies prevents the development of osteolytic lesions and inhibits tumor growth [ 33 ]. Similar results have been shown with MLN3897, a specific orally available CCR1 inhibitor. This drug inhibits both OC formation and MM cell proliferation [ 122 ]. Further clinical trials on patients with MM bone disease will be needed to confirm these interesting preliminary data.
DKK-1 Antagonists . It is well known that the Wnt inhibitor DKK-1 plays a key role in mediating OB inhibition in MM [ 123 ]. Thus, numerous strategies to block DKK-1 activity have been developed. In vitro assays show that DKK-1 inhibition via a specific neutralizing antibody promote OB differentiation and function [ 86 , 124 ]. Moreover, in vivo studies using DKK-1 inhibitors on murine and humanized models of MM-induced bone disease show increased OB number and bone formation, thus resulting in osteolytic lesion improvement [ 87 , 125 ]. Moreover, blocking DKK-1 also resulted in reduction of tumor growth [ 124 ]. Currently, phase 1 clinical trials are ongoing combining DKK-1-neutralizing antibody and bisphosphonates. In particular, BHQ880, an anti-DKK-1 monoclonal antibody, in combination with zoledronic acid is being studied.
Activin A Antagonists . Activin A, a cytokine upregulated in MM patients with extensive bone disease [ 81 ], is able to both stimulate OC differentiation and inhibit OB formation. In two myeloma mouse models, the administration of an Activin A chimeric inhibitor (RAP-011) derived from the fusion of the extracellular domain of activin receptor IIA and the constant domain of the murine IgG2a [ 126 ] or a soluble Activin A receptor type IIA fusion protein (ActRIIA.muFc) blocks the development of osteolytic bone lesions by both inhibiting OC development and stimulating osteoblastogenesis [ 80 , 127 ]. Moreover, RAP-011 effectively reduced tumor growth [ 80 ]. It was just demonstrated that the humanized counterpart of RAP-011, sotatercept (ACE-011), stimulates bone formation and inhibits bone resorption markers in postmenopausal women. Thus, the inhibition of Activin A may be a promising approach for the treatment of myeloma-related bone lesions. Ongoing clinical trials are evaluating sotatercept role in MM.
11. Conclusions
Recently, a lot of studies demonstrated a close relationship between the immune and skeletal systems as well as tumor growth and bone cell activity in MM bone disease. Nowadays, it is evident that not only MM cells but also bone cells, BMSCs, and immune cells are critical players in the pathogenesis of MM bone disease, thus contributing to the development of osteolysis. These cells as well as their products participate in both OC development and OB inhibition leading to bone destruction in MM. In the BM microenvironment, a vicious circle between the bone destructive process and tumor progression that feed each other was maintained. Thus, the inhibition of bone resorption could decrease both myeloma bone disease and tumor progression. The discovery of novel agents with dual activity on bone remodelling may also result in improvement of bone disease besides prevention of osteolytic lesions. Therefore, agents restoring bone balance in MM represent a novel strategy to overcome osteolytic disease and MM tumor growth.
Acknowledgment
This work is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, Grant no. IG_11957 to Maria Grano).
1 Kyle RA Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 2009 23 1 3 9 2-s2.0-58249097191 18971951 10.1038/leu.2008.291 PMC2627786
2 Landgren O Kyle RA Pfeiffer RM Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 2009 113 22 5412 5417 2-s2.0-67049162188 19179464 10.1182/blood-2008-12-194241 PMC2689042
3 Weiss BM Abadie J Verma P Howard RS Kuehl WM A monoclonal gammopathy precedes multiple myeloma in most patients Blood 2009 113 22 5418 5422 2-s2.0-67049114114 19234139 10.1182/blood-2008-12-195008 PMC2689043
4 Kyle RA Kumar S The significance of monoclonal gammopathy of undetermined significance Haematologica 2009 94 12 1641 1644 2-s2.0-73149115752 19996115 10.3324/haematol.2009.013961 PMC2791927
5 Kyle RA Rajkumar SV Multiple myeloma The New England Journal of Medicine 2004 351 18 1860 1873 2-s2.0-6944235003 15509819 10.1056/NEJMra041875
6 Saad F Lipton A Cook R Chen Y Smith M Coleman R Pathologic fractures correlate with reduced survival in patients with malignant bone disease Cancer 2007 110 8 1860 1867 2-s2.0-35048875471 17763372 10.1002/cncr.22991
7 Sonmez M Akagun T Topbas M Effect of pathologic fractures on survival in multiple myeloma patients: a case control study Journal of Experimental and Clinical Cancer Research 2008 27 1, article 11 2-s2.0-52949131560 10.1186/1756-9966-27-11 PMC2438338 18577267
8 Björkstrand B Iacobelli S Hegenbart U Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up Journal of Clinical Oncology 2011 29 22 3016 3022 2-s2.0-80051642093 21730266 10.1200/JCO.2010.32.7312
9 Cook G Campbell JDM Immune regulation in multiple myeloma: the host-tumour conflict Blood Reviews 1999 13 3 151 162 2-s2.0-0032873880 10527267 10.1054/blre.1999.0111
10 Gupta GP Massagué J Cancer metastasis: building a framework Cell 2006 127 4 679 695 2-s2.0-33751252276 17110329 10.1016/j.cell.2006.11.001
11 Amé-Thomas P Hajjami HM Monvoisin C Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis Blood 2007 109 2 693 702 2-s2.0-33846255324 16985173 10.1182/blood-2006-05-020800
12 Hideshima T Mitsiades C Tonon G Richardson PG Anderson KC Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nature Reviews Cancer 2007 7 8 585 598 2-s2.0-34547106018 17646864 10.1038/nrc2189
13 Chauhan D Uchiyama H Akbarali Y Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- κ B Blood 1996 87 3 1104 1112 2-s2.0-0030041147 8562936
14 Roodman GD Mechanisms of bone metastasis The New England Journal of Medicine 2004 350 16 1655 1664 2-s2.0-4644261592 15084698 10.1056/NEJMra030831
15 Giuliani N Rizzoli V Roodman GD Multiple myeloma bone disease: pathophysiology of osteoblast inhibition Blood 2006 108 13 3992 3996 2-s2.0-33751193178 16917004 10.1182/blood-2006-05-026112
16 Bataille R Chappard D Marcelli C Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease Journal of Clinical Oncology 1989 7 12 1909 1914 2-s2.0-0024786736 2585025 10.1200/JCO.1989.7.12.1909
17 Yang CR Wang JH Hsieh SL Wang SM Hsu TL Lin WW Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells Cell Death and Differentiation 2004 11 1 S97 S107 2-s2.0-4344605748 15002040 10.1038/sj.cdd.4401403
18 Brunetti G Oranger A Mori G The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3 Annals of the New York Academy of Sciences 2010 1192 298 302 2-s2.0-77950641605 20392250 10.1111/j.1749-6632.2009.05304.x
19 Colucci S Brunetti G Mori G Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients Leukemia 2009 23 11 2139 2146 2-s2.0-70450240910 19587706 10.1038/leu.2009.136
20 Lee JW Chung HY Ehrlich LA IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells Blood 2004 103 6 2308 2315 2-s2.0-1542313900 14615378 10.1182/blood-2003-06-1992
21 Barton BE Mayer R IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells Journal of Immunology 1989 143 10 3211 3216 2-s2.0-0024326940 2809196
22 Ehrlich LA Chung HY Ghobrial I EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma Blood 2005 106 4 1407 1414 2-s2.0-23744507989 15878977 10.1182/blood-2005-03-1080
23 Merico F Bergui L Gregoretti MG Ghia P Aimo G Lindley IJD Cytokines involved in the progression of multiple myeloma Clinical and Experimental Immunology 1993 92 1 27 31 2-s2.0-0027405780 8467562 10.1111/j.1365-2249.1993.tb05943.x PMC1554871
24 Uneda S Hata H Matsuno F Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM British Journal of Haematology 2003 120 1 53 55 2-s2.0-0037219741 12492576 10.1046/j.1365-2141.2003.04040.x
25 Man JH Choi SJ Kurihara N Koide M Oba Y Roodman GD Macrophage inflammatory protein-1 α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κ B ligand Blood 2001 97 11 3349 3353 2-s2.0-0035383761 11369623 10.1182/blood.v97.11.3349
26 Abe M Hiura K Wilde J Role for macrophage inflammatory protein (MIP)-1 α and MIP-1 β in the development of osteolytic lesions in multiple myeloma Blood 2002 100 6 2195 2202 2-s2.0-0037105599 12200385
27 Choi SJ Cruz JC Craig F Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 2000 96 2 671 675 2-s2.0-0342322717 10887133
28 Wolpe SD Davatelis G Sherry B Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties Journal of Experimental Medicine 1988 167 2 570 581 2-s2.0-0023841073 3279154 10.1084/jem.167.2.570 PMC2188834
29 Kukita T Nomiyama H Ohmoto Y Macrophage inflammatory protein-1 α (LD78) expressed in human bone marrow: iIts role in regulation of hematopoiesis and osteoclast recruitment Laboratory Investigation 1997 76 3 399 406 2-s2.0-0030903039 9121122
30 Scheven BAA Milne JS Hunter I Robins SP Macrophage-inflammatory protein-1 α regulates preosteoclast differentiation in vitro Biochemical and Biophysical Research Communications 1999 254 3 773 778 2-s2.0-0033608227 9920817 10.1006/bbrc.1998.9909
31 Rivollier A Mazzorana M Tebib J Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment Blood 2004 104 13 4029 4037 2-s2.0-10244259169 15308576 10.1182/blood-2004-01-0041
32 Lentzsch S Gries M Janz M Bargou R Dörken B Mapara MY Macrophage inflammatory protein 1-alpha (MIP-1 α ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells Blood 2003 101 9 3568 3573 2-s2.0-0038386032 12506012 10.1182/blood-2002-08-2383
33 Choi SJ Oba Y Gazitt Y Antisense inhibition of macrophage inflammatory protein 1- α blocks bone destruction in a model of myeloma bone disease Journal of Clinical Investigation 2001 108 12 1833 1841 2-s2.0-0035664488 11748267 10.1172/JCI13116 PMC209465
34 Oyajobi BO Franchin G Williams PJ Dual effects of macrophage inflammatory protein-1 α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood 2003 102 1 311 319 2-s2.0-0038579121 12649140 10.1182/blood-2002-12-3905
35 Vallet S Raje N Ishitsuka K MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts Blood 2007 110 10 3744 3752 2-s2.0-36348988548 17715391 10.1182/blood-2007-05-093294 PMC2077320
36 Roodman GD Mechanisms of bone lesions in multiple myeloma and lymphoma Cancer 1997 80 8 1557 1563 2-s2.0-0030791806 9362422 10.1002/(sici)1097-0142(19971015)80:8+<1557::aid-cncr5>3.3.co;2-k
37 Lacey DL Tan HL Lu J Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo The American Journal of Pathology 2000 157 2 435 448 2-s2.0-0033888977 10934148 10.1016/S0002-9440(10)64556-7 PMC1850124
38 Lacey DL Timms E Tan HL Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998 93 2 165 176 2-s2.0-0032540319 9568710 10.1016/s0092-8674(00)81569-x
39 Grano M Brunetti G Colucci S Immunomodulation of multiple myeloma bone disease Clinical Reviews in Bone and Mineral Metabolism 2009 7 4 293 300 2-s2.0-70449521102
40 Heider U Langelotz C Jakob C Expression of receptor activator of nuclear factor κ B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clinical Cancer Research 2003 9 4 1436 1440 2-s2.0-0037389602 12684416
41 Sezer O Heider U Jakob C Eucker J Possinger K Human bone marrow myeloma cells express RANKL Journal of Clinical Oncology 2002 20 1 353 354 2-s2.0-0036140071 10.1200/JCO.2002.20.1.353 11773196
42 Sezer O Heider U Jakob C Immunocytochemistry reveals RANKL expression of myeloma cells Blood 2002 99 12 4646 4647 2-s2.0-0037097587 12066787 10.1182/blood-2002-01-0148
43 Croucher PI Shipman CM Lippitt J Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 2001 98 13 3534 3540 2-s2.0-0035895055 11739154 10.1182/blood.v98.13.3534
44 Colucci S Brunetti G Rizzi R T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction Blood 2004 104 12 3722 3730 2-s2.0-9444231136 15308561 10.1182/blood-2004-02-0474
45 Giuliani N Bataille R Mancini C Lazzaretti M Barillé S Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 2001 98 13 3527 3533 2-s2.0-0035895083 11739153 10.1182/blood.v98.13.3527
46 Pearse RN Sordillo EM Yaccoby S Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11581 11586 2-s2.0-0035949510 11562486 10.1073/pnas.201394498 PMC58772
47 Roux S Meignin V Quillard J RANK (receptor activator of nuclear factor- κ B) and RANKL expression in multiple myeloma British Journal of Haematology 2002 117 1 86 92 2-s2.0-0036223310 11918537 10.1046/j.1365-2141.2002.03417.x
48 Brunetti G Colucci S Rizzi R The role of OPG/TRAIL complex in multiple myeloma Annals of the New York Academy of Sciences 2006 1068 1 334 340 2-s2.0-33744745283 16831934 10.1196/annals.1346.049
49 Jakob C Goerke A Terpos E Serum levels of total-RANKL in multiple myeloma Clinical Lymphoma and Myeloma 2009 9 6 430 435 2-s2.0-72549108623 19951882 10.3816/CLM.2009.n.085
50 Oshima T Abe M Asano J Myeloma cells suppress osteoblast differentiation by secreting a soluble wnt inhibitor, sFRP-2 Blood 2004 104 p. 2356 10.1182/blood-2004-12-4940 16030194
51 De Vos J Couderc G Tarte K Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays Blood 2001 98 3 771 780 2-s2.0-0035437195 11468178 10.1182/blood.v98.3.771
52 Giuliani N Morandi F Tagliaferri S Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment Cancer Research 2007 67 16 7665 7674 2-s2.0-34548008809 17702698 10.1158/0008-5472.CAN-06-4666
53 Tian E Zhan F Walker R The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 14695408 10.1056/NEJMoa030847
54 Colucci S Brunetti G Oranger A Myeloma cells suppress osteoblasts through sclerostin secretion Blood Cancer Journal 2011 1 6, article e27 10.1038/bcj.2011.22 PMC3255263 22829171
55 Nusse R WNT targets: repression and activation Trends in Genetics 1999 15 1 1 3 2-s2.0-0032916351 10087922 10.1016/s0168-9525(98)01634-5
56 Moon RT Brown JD Torres M WNTs modulate cell fate and behavior during vertebrate development Trends in Genetics 1997 13 4 157 162 2-s2.0-0031128225 9097727 10.1016/s0168-9525(97)01093-7
57 Gong Y Slee RB Fukai N LDL receptor related protein 5 (LRP5) affects bone accrual and eye development Cell 2001 107 513 523 11719191 10.1016/s0092-8674(01)00571-2
58 Cadigan KM Nusse R Wnt signaling: a common theme in animal development Genes and Development 1997 11 24 3286 3305 2-s2.0-0031456158 9407023 10.1101/gad.11.24.3286
59 Miller JR Hocking AM Brown JD Moon RT Mechanism and function of signal transduction by the Wnt/B-catenin and Wnt/Ca2 + pathways Oncogene 1999 18 55 7860 7872 2-s2.0-0033590172 10630639 10.1038/sj.onc.1203245
60 Krishnan V Bryant HU MacDougald OA Regulation of bone mass by Wnt signaling Journal of Clinical Investigation 2006 116 5 1202 1209 2-s2.0-33646433058 16670761 10.1172/JCI28551 PMC1451219
61 Qiang YW Chen Y Stephens O Myeloma-derived dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma Blood 2008 112 1 196 207 2-s2.0-47249140444 18305214 10.1182/blood-2008-01-132134 PMC2435688
62 Brunetti G Oranger A Mori G Sclerostin is overexpressed by plasma cells from multiple myeloma patients Annals of the New York Academy of Sciences 2011 1237 1 19 23 2-s2.0-81255210568 22082361 10.1111/j.1749-6632.2011.06196.x
63 Terpos E Christoulas D Katodritou E Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy International Journal of Cancer 2011 131 6 1466 1471 2-s2.0-83755178943 22052418 10.1002/ijc.27342
64 Nanes MS Tumor necrosis factor- α : molecular and cellular mechanisms in skeletal pathology Gene 2003 321 1-2 1 15 2-s2.0-0242409906 14636987 10.1016/s0378-1119(03)00841-2
65 Kitaura H Sands MS Aya K Marrow stromal cells and osteoclast precursors differentially contribute to TNF- α -induced osteoclastogenesis in vivo Journal of Immunology 2004 173 8 4838 4846 2-s2.0-6344293669 10.4049/jimmunol.173.8.4838 15470024
66 Hideshima T Chauhan D Podar K Schlossman RL Richardson P Anderson KC Novel therapies targeting the myeloma cell and its bone marrow microenvironment Seminars in Oncology 2001 28 6 607 612 2-s2.0-0035211881 11740818 10.1016/s0093-7754(01)90033-8
67 Ghali O Chauveau C Hardouin P Broux O Devedjian J TNF- α ’s effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression Journal of Bone and Mineral Research 2010 25 7 1616 1626 2-s2.0-77954699441 20200969 10.1002/jbmr.52
68 Esteve F Hong CS Huston A Suppression of mesenchymal stromal cell (MSC) differentiation in multiple myeloma (MM) is restricted to the osteoblast lineage Blood 2008
69 D'Souza S Del Prete D Sammut B Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses runx2 expression and osteoblast differentiation Proceedings of the 9th International Meeting on Cancer Induced Bone Disease 2009 Arlington, Va, USA University of Pittsburgh
70 D'Souza S Del Prete D Esteve F Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses osteoblast differentiation in patients with myeloma Blood 2009 114 p. 742
71 Hideshima T Bergsagel PL Kuehl WM Anderson KC Advances in biology of multiple myeloma: clinical applications Blood 2004 104 3 607 618 2-s2.0-3242777803 15090448 10.1182/blood-2004-01-0037
72 Uchiyama H Barut BA Mohrbacher AF Chauhan D Anderson KC Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion Blood 1993 82 12 3712 3720 2-s2.0-0027133422 8260708
73 Gupta D Treon SP Shima Y Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 2001 15 12 1950 1961 2-s2.0-0035195019 11753617 10.1038/sj.leu.2402295
74 Dankbar B Padró T Leo R Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma Blood 2000 95 8 2630 2636 2-s2.0-0034655957 10753844
75 Lowik CWGM Van Der Pluijm G Bloys H Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis Biochemical and Biophysical Research Communications 1989 162 3 1546 1552 2-s2.0-0024404268 2548501 10.1016/0006-291x(89)90851-6
76 Tai YT Li XF Breitkreutz I Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment Cancer Research 2006 66 13 6675 6682 2-s2.0-33746122751 16818641 10.1158/0008-5472.CAN-06-0190
77 Neri P Kumar S Fulciniti MT Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model Clinical Cancer Research 2007 13 19 5903 5909 2-s2.0-35348915408 17908986 10.1158/1078-0432.CCR-07-0753
78 Moreaux J Legouffe E Jourdan E BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone Blood 2004 103 8 3148 3157 2-s2.0-11144355586 15070697 10.1182/blood-2003-06-1984 PMC2387243
79 Hemingway F Taylor R Knowles HJ Athanasou NA RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II Bone 2011 48 4 938 944 2-s2.0-79952699649 21193069 10.1016/j.bone.2010.12.023
80 Vallet S Mukherjee S Vaghela N Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease Proceedings of the National Academy of Sciences of the United States of America 2010 107 11 5124 5129 2-s2.0-77950438331 20194748 10.1073/pnas.0911929107 PMC2841922
81 Terpos E Kastritis E Christoulas D Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy Annals of Oncology 2012 23 10 2681 2686 22492699 10.1093/annonc/mds068
82 Terpos E Politou M Szydlo R Goldman JM Apperley JF Rahemtulla A Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 α ) correlate with the extent of bone disease and survival in patients with multiple myeloma British Journal of Haematology 2003 123 1 106 109 2-s2.0-0141707692 14510950 10.1046/j.1365-2141.2003.04561.x
83 Karadag A Oyajobi BO Apperley JF Graham R Russell G Croucher PI Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts British Journal of Haematology 2000 108 2 383 390 2-s2.0-0034012201 10691869 10.1046/j.1365-2141.2000.01845.x
84 Shipman CM Croucher PI Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Research 2003 63 5 912 916 2-s2.0-0037374460 12615702
85 Yaccoby S Ling W Zhan F Walker R Barlogie B Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 2007 109 5 2106 2111 2-s2.0-33847397091 17068150 10.1182/blood-2006-09-047712 PMC1801040
86 Edwards CM Edwards JR Lwin ST Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo Blood 2008 111 5 2833 2842 2-s2.0-41949093576 18094333 10.1182/blood-2007-03-077685 PMC2254537
87 Fulciniti M Tassone P Hideshima T Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma Blood 2009 114 2 371 379 2-s2.0-67650431302 19417213 10.1182/blood-2008-11-191577 PMC2714212
88 Giuliani N Ferretti M Bolzoni M Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation Leukemia 2012 26 6 1391 1401 22289923 10.1038/leu.2011.381
89 Teitelbaum SL Postmenopausal osteoporosis, T cells, and immune dysfunction Proceedings of the National Academy of Sciences of the United States of America 2004 101 48 16711 16712 2-s2.0-10044225587 15557556 10.1073/pnas.0407335101 PMC534741
90 Rifas L Arackal S T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism Arthritis and Rheumatism 2003 48 4 993 1001 2-s2.0-0037388342 12687541 10.1002/art.10872
91 Kay N Leong T Kyle RA Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487) Leukemia and Lymphoma 1999 33 1-2 127 133 2-s2.0-0032970781 10194129 10.3109/10428199909093733
92 Mellstedt H Holm G Pettersson D T cells in monoclonal gammopathies Scandinavian Journal of Haematology 1982 29 1 57 64 2-s2.0-0019968869 6214842 10.1111/j.1600-0609.1982.tb00563.x
93 Tienhaara A Pelliniemi T Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance Clinical and Laboratory Haematology 1994 16 3 213 223 2-s2.0-0028136913 7828409 10.1111/j.1365-2257.1994.tb00414.x
94 Joshua DE Brown RD Ho PJ Gibson J Regulatory T cells and multiple myeloma Clinical Lymphoma and Myeloma 2008 8 5 283 286 2-s2.0-58149327333 18854282 10.3816/CLM.2008.n.039
95 Peng L Kjaergäard J Plautz GE Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy Journal of Immunology 2002 169 9 4811 4821 2-s2.0-0036839149 10.4049/jimmunol.169.9.4811 12391191
96 Zhou G Levitsky HI Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance Journal of Immunology 2007 178 4 2155 2162 2-s2.0-33846913897 10.4049/jimmunol.178.4.2155 17277120
97 Curiel TJ Coukos G Zou L Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 2-s2.0-4644237613 10.1038/nm1093 15322536
98 Woo EY Chu CS Goletz TJ Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 2-s2.0-0035874949 11406550
99 Liyanage UK Moore TT Joo H Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma Journal of Immunology 2002 169 5 2756 2761 2-s2.0-0036721629 10.4049/jimmunol.169.5.2756 12193750
100 Beyer M Kochanek M Giese T In vivo peripheral expansion of naive CD4 + CD25 high FoxP3 + regulatory T cells in patients with multiple myeloma Blood 2006 107 10 3940 3949 2-s2.0-33646575622 16410445 10.1182/blood-2005-09-3671
101 Brimnes MK Vangsted AJ Knudsen LM Increased level of both CD4 + FOXP3 + regulatory T cells and CD14 + HLA-DR − /low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma Scandinavian Journal of Immunology 2010 72 6 540 547 2-s2.0-78149270433 21044128 10.1111/j.1365-3083.2010.02463.x
102 Feyler S Von Lilienfeld-Toal M Jarmin S CD4 + CD25 + FoxP3 + regulatory T cells are increased whilst CD3 + CD4 − CD8- αβ TCR + Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden British Journal of Haematology 2009 144 5 686 695 2-s2.0-58849093606 19133978 10.1111/j.1365-2141.2008.07530.x
103 Prabhala RH Neri P Bae JE Dysfunctional T regulatory cells in multiple myeloma Blood 2006 107 1 301 304 2-s2.0-30144444962 16150935 10.1182/blood-2005-08-3101 PMC1895365
104 Dhodapkar KM Barbuto S Matthews P Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma Blood 2008 112 7 2878 2885 2-s2.0-53449089919 18669891 10.1182/blood-2008-03-143222 PMC2556623
105 Prabhala RH Pelluru D Fulciniti M Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma Blood 2010 115 26 5385 5392 2-s2.0-77955862810 20395418 10.1182/blood-2009-10-246660 PMC2902136
106 Noonan K Marchionni L Anderson J Pardoll D Roodman GD Borrello I A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma Blood 2010 116 18 3554 3563 2-s2.0-78149322663 20664052 10.1182/blood-2010-05-283895 PMC4017298
107 Giuliani N Morandi F Tagliaferri S Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients Blood 2006 107 2 841 842 2-s2.0-30444432403 16401825 10.1182/blood-2005-07-2719
108 Colucci S Brunetti G Grano M Immunoregulation of osteoclast differentiation in multiple myeloma bone disease Bone Cancer: Progression and Therapeutic Approaches 2010 chapter 6 Elsevier 67 75 Section II: Bone Microenvironment and Bone Cancer
109 Giuliani N Colla S Sala R Human myeloma cells stimulate the receptor activator of nuclear factor- κ B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease Blood 2002 100 13 4615 4621 2-s2.0-0037114636 12393684 10.1182/blood-2002-04-1121
110 Iwata M Graf L Awaya N Torok-Storb B Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein Blood 2002 100 4 1318 1325 2-s2.0-0037103193 12149213 10.1182/blood-2002-01-0062
111 Giuliani N Colla S Morandi F Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation Blood 2005 106 7 2472 2483 2-s2.0-23744498205 15933061 10.1182/blood-2004-12-4986
112 Banchereau J Briere F Caux C Immunobiology of dendritic cells Annual Review of Immunology 2000 18 767 811 2-s2.0-0034041033 10.1146/annurev.immunol.18.1.767 10837075
113 Wang S Yang J Qian J Wezeman M Kwak LW Yi Q Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma Blood 2006 107 6 2432 2439 2-s2.0-33644757687 16291589 10.1182/blood-2005-06-2486 PMC1895733
114 Brown RD Pope B Murray A Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- β 1 and interleukin-10 Blood 2001 98 10 2992 2998 2-s2.0-0035892109 11698282 10.1182/blood.v98.10.2992
115 Wang S Hong S Yang J Optimizing immunotherapy in multiple myeloma: Restoring the function of patients’ monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Blood 2006 108 13 4071 4077 2-s2.0-33845482670 16917008 10.1182/blood-2006-04-016980 PMC1895445
116 Ratta M Fagnoni F Curti A Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6 Blood 2002 100 1 230 237 2-s2.0-0036659945 12070032 10.1182/blood.v100.1.230
117 Onishi Y Fehervari Z Yamaguchi T Sakaguchi S Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation Proceedings of the National Academy of Sciences of the United States of America 2008 105 29 10113 10118 2-s2.0-48249103057 18635688 10.1073/pnas.0711106105 PMC2481354
118 Fizazi K Lipton A Mariette X Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates Journal of Clinical Oncology 2009 27 10 1564 1571 2-s2.0-63749094012 19237632 10.1200/JCO.2008.19.2146
119 Body J Greipp P Coleman RE A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 2003 97 3 887 892 2-s2.0-0346837985 12548591 10.1002/cncr.11138
120 Abe M Hiura K Wilde J Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood 2004 104 8 2484 2491 2-s2.0-4944230728 15187021 10.1182/blood-2003-11-3839
121 Neri P Kumar S Fulciniti MT Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model Clinical Cancer Research 2007 13 19 5903 5909 2-s2.0-35348915408 17908986 10.1158/1078-0432.CCR-07-0753
122 Vallet S Raje N Ishitsuka K MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts Blood 2007 110 10 3744 3752 2-s2.0-36348988548 17715391 10.1182/blood-2007-05-093294 PMC2077320
123 Tian E Zhan F Walker R The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 14695408 10.1056/NEJMoa030847
124 Pozzi S Yan H Vallet S Preclinical validation of a novel Dkk-1 neutralizing antibody for the treatment of multiple myeloma related bone disease Proceedings of the ASBMR 30th Annual Meeting September 2008 Montreal, Canada 12 16
125 Heath DJ Chantry AD Buckle CH Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma Journal of Bone and Mineral Research 2009 24 3 425 436 2-s2.0-61849137831 19016584 10.1359/jbmr.081104
126 Pearsall RS Canalis E Cornwall-Brady M A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity Proceedings of the National Academy of Sciences of the United States of America 2008 105 19 7082 7087 2-s2.0-44349141964 18460605 10.1073/pnas.0711263105 PMC2383948
127 Chantry AD Heath D Mulivor AW Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo Journal of Bone and Mineral Research 2010 25 2633 2646 20533325 10.1002/jbmr.142